Chemokine (C-C motif) ligand 5 (CCL5) belongs to a group of chemokines that play a role in the peripheral immune system, mostly as chemoattractant molecules, and mediate tactile allodynia. In the central nervous system (CNS), CCL5 and its receptors have multiple functions, including promoting neuroinflammation, insulin signaling, neuromodulator of synaptic activity and neuroprotection against a variety of neurotoxins. Evidence has also suggested that this chemokine may regulate opioid response. The multifunctional profile of CCL5 might correlate with its ability to bind different chemokine receptors, as well as with its unique cellular expression. In this work, we have used fluorescence in situ hybridization combined with immunohistochemistry to examine the expression profile of CCL5 mRNA in the adult rat brain and provide evidence of its cellular localization. We have observed that the highest expression of CCL5 mRNA occurs in all major fiber tracts, including the corpus callosum, anterior commissure, and cerebral peduncle. In these tracts, CCL5 mRNA was localized in oligodendrocytes, astrocytes and microglia. Astrocytic and microglial expression was also evident in several brain areas including the cerebral cortex, caudate/putamen, hippocampus, and thalamus. Furthermore, using a specific neuronal marker, we observed CCL5 mRNA expression in discrete layers of the cortex and hippocampus. Interestingly, in the midbrain, CCL5 mRNA co-localized with tyrosine hydroxylase (TH) positive cells of the ventral tegmental area, suggesting that CCL5 might be expressed by a subset of dopaminergic neurons of the mesolimbic system. The expression of CCL5 mRNA and protein, together with its receptors, in selected brain cell populations proposes that this chemokine could be involved in neuronal/glial communication.
INTRODUCTION
Chemokines belong to the cytokine family of peptides that induce the maturation and trafficking of leukocytes and are considered to be essential for the inflammatory responses of the immune system. Some chemokines have been linked to pro-inflammatory events, associated with chronic pain (White et al., 2005) or brain diseases such as human immunodeficiency virus (HIV)-associated dementia (Schmidtmayerova et al., 1996; Conant et al., 1998) , multiple sclerosis (Hvas et al., 1997; McManus et al., 1998; Rentzos et al., 2007) , stroke (Siniscalchi et al., 2014) or traumatic brain injury .
Of particular interest is the chemokine (C-C motif) ligand 5 (CCL5), formerly known as Regulated on Activation Normal T-cell Expressed and Secreted (RANTES). CCL5 is a small protein of 68 amino acids that activate mononuclear phagocytes and induce their migration across the blood brain barrier to the site of inflammation (Ubogu et al., 2006) . The role of CCL5 in inflammation has also been inferred by an association between increased CCL5 protein expression and the degree of inflammation in a variety of disorders and pathologies, including neuropathic pain (Bhangoo et al., 2007) , asthma, atherosclerosis and arthritis among others (Marques et al., 2013) . However, in the brain, CCL5 function goes beyond the one attributed to a classic pro-inflammatory chemokine. In fact, CCL5 is capable of inducing proliferation of Oli-neu, an oligodendrocyte precursor-like cell line (Kadi et al., 2006) suggesting a role in myelination. Moreover, CCL5 promotes the migration of dorsal root ganglia cells in vitro (Bolin et al., 1998) , and regulates the differentiation of astrocytes (Bakhiet et al., 2001) suggesting that CCL5 may act as a neurotrophic factor. In addition, ex vivo activation of CCL5 receptor (CCR5) by CCL5 increases glucose transporter type 4 membrane translocation in the hypothalamus (Chou et al., 2016) , suggesting a role of CCL5 in glucose uptake and metabolism. These examples highlight the potential role of CCL5 as a modulator of cellular metabolism and brain architecture. Lastly, CCL5 exerts neuroprotective activity against various neurotoxins including glutamate (Bruno et al., 2000) , β-amyloid (Ignatov et al., 2006) , and the HIV proteins gp120 (Campbell et al., 2015) and tat (Rozzi et al., 2014) . The different effects of CCL5 could be due to the ability of this chemokine to bind to multiple receptors. The selective and differential expression of CCL5 and its receptors, CCR5 (Avdoshina et al., 2011) , CCR3 (He et al., 1997) and CCR1 (Tran et al., 2007) in the rodent brain supports the role of CCL5 as a potential modulator of brain homeostasis. Nevertheless, the functional role of CCL5 in the brain could be more in line with the suggested properties of some chemokines to act as a third neurotransmitter system (Adler et al., 2005) helping neuronal communication (Rostene et al., 2007) , perhaps through modulation of the release of glutamate from nerve endings (Musante et al., 2008) .
CCL5 is constitutively expressed in the adult central nervous system (CNS; Campbell et al., 2013) . Nevertheless, the type of cells that express CCL5 has been so far inferred by in vitro studies. For instance, astrocytes appear to express CCL5 at high levels (Avdoshina et al., 2010) ; nevertheless, oligodendrocytes (Balabanov et al., 2007) , microglia (Avdoshina et al., 2010) and neurons , all release CCL5. In this study, we have analyzed CCL5 mRNA expression patterns in the rat brain using in situ hybridization combined with immunohistochemistry to detect specific cell types (Grabinski et al., 2015; Lanfranco et al., 2017) . This method showed adequate sensitivity and specificity to detect mRNA transcripts of the CCL5 gene. Our results show that CCL5 mRNA follows a cellular and anatomical distribution, which is highly regionalized and restricted to certain parts of the brain. We provide evidence for the first time that CCL5 mRNAs can be expressed in dopamineproducing neurons.
MATERIALS AND METHODS

Animals
Two month-old C57BL/6J (wild-type, WT) and CCL5 knock-out (KO, B6.129P2-Ccl5tm1) male mice (22-25 g) were purchased from The Jackson Laboratory (Bar Harbor, ME, USA). CCL5 KO mice have been validated by northern blot analysis of total RNA isolated from LPS-stimulated peritoneal exudate cells (Makino et al., 2002) . Three-month-old male Sprague-Dawley (SD) rats (225-250 g) were purchased from Charles River Laboratory (Germantown, MD, USA). Animals were housed under standard conditions with food and water ad libitum and maintained on a 12-h light/dark cycle. Animals were anesthetized with a mixture of ketamine/xylazine (80 mg/kg and 10 mg/kg, i.p.) and intracardially perfused with ice-cold phosphate buffered saline (PBS) followed by perfusion with 4% paraformaldehyde (PFA). After perfusion, whole brains were quickly removed and post-fixed in 4% PFA overnight and transferred sequentially into a 10%, 20% and 30% sucrose solution. Post-fixed brains were used for RNA in situ hybridization and immunohistochemistry studies. All studies were carried out following the Guide for the Care and Use of Laboratory Animals as adopted and promulgated by the U.S. National Institutes of Health and approved by Georgetown University Animal Care and Use Committee.
RNAscope in Situ Hybridization Combined with Immunohistochemistry
A sliding microtome (microm HM 430, Thermo Fisher Scientific, Tustin, CA, USA) was used to cut the brains in coronal orientation. The brain sections (20 µm thickness) were cryoprotected in an antifreeze solution (30% glycerol + 30% ethylene glycol + 0.01 M PBS) for storage at −20 • C. Free-floating brain sections were washed three times in PBS before mounting in Gold Seal TM UltraStick TM Adhesion Microscope Slides Thermo Fisher Scientific) . Tissue was allowed to dry at room temperature (RT) and then stored at −20 • C until use. RNAscope in situ hybridization assay was performed according to manufacturer's instructions (Advance Cell Diagnostics (ACD), Hayward, CA, USA). In short, mounted tissue sections were serially dehydrated in 50%, 70%, 95%, 100% and 100% ethanol for 5 min each. In between all pretreatment steps, tissue sections were briefly washed with ultra-pure water. Incubation periods were performed on the HybEz TM hybridization system (ACD). The pretreat solution 1 (hydrogen peroxide reagent) was applied for 10 min at RT and then the tissue sections were boiled in pretreat solution 2 (target retrieval reagent) for 15 min. Mounted slices were treated with pretreat solution 3 (protease reagent) for 30 min at 40 • C. Custom rat CCL5 RNAscope probe was designed and purchased from ACD. CCL5 probe targets the region 14-556 (Accession number: NM_031116.3) of the CCL5 sequence with 12 pairs of ZZ-target probes. In addition, the negative (Cat. No. 310043, ACD) and positive (Cat. No. 313911, ACD) control probes were applied and let hybridized for 2 h at 40 • C. The amplification steps were performed according to manufacturer's directions. In between every amplification step, sections were washed with 1× wash buffer. Detection was performed using a mixture ratio of Red-A to Red-B solution of 1:60. The sections were incubated for 10 min at RT and rinsed with ultra-pure water.
Following in situ hybridization, the sections were processed for immunohistochemistry. Briefly, following the blocking step with 5% normal goat serum (NGS) in PBS for 1 h at RT, post-hybridized slides were incubated with an antibody against glial fibrillary acidic protein (GFAP, 1:1000, EMD Millipore, Temecula, CA, USA), ionized calcium binding adaptor molecule-1 (Iba-1, 1:500, Wako Chemical USA, Richmond, VA, USA), homeobox protein transcription factor Nkx2.2 (1:100, EMD Millipore), neuronal nuclear antigen (NeuN, 1:100, EMD Millipore) or tyrosine hydroxylase (TH, 1:500, EMD Millipore) in the presence of 2% NGS in PBS overnight at 4 • C. Brain slices treated with NeuN antibody were incubated for 72 h at 4 • C. Subsequent to three washes with PBS, the slides were incubated with corresponding Alexa Fluor 488 secondary antibodies (1:500; Molecular probes , Thermo Fisher Scientific) for 2 h at RT. Brain sections were rinsed with PBS three times and incubated for 5 min in PBS with DAPI solution (1:50,000, Sigma-Aldrich, St. Louis, MO, USA) for counterstained nuclei.
Images Acquisition and Quantitative Analysis
Anatomical structures were analyzed in coronal sections and mapped according to Paxinos and Watson atlas (Paxinos and Watson, 1998) . Fluorescent signals of CCL5 mRNA hybridization and immunohistochemistry for different cell types were imaged with a 10×, 20×, 40× and 63× objective lens on a Leica SP8 confocal microscope (Leica Microsystems Inc., Buffalo Grove, IL, USA) and an Axioplan 2 microscope (Zeiss, Thorwood, NY, USA) with a Photometrics camera. All microscope and camera settings were identical for all images. The color label to far red (Excitation 647 nm, Emission 690 nm) was assigned for mRNA hybridization signal. The color label to green was assigned for the antigen of interest (Excitation 490 nm, Emission 525 nm). The number of CCL5 mRNA positive/cell type marker, and the total number of CCL5 mRNA positive cells were quantified in five (corpus callosum and cortex) and three (hippocampus and VTA) microscopic fields per brain section (20X, 151.894 mm 2 ), using the ImageJ64 software (National Institute of Health. Bethesda, MD, USA), as previously described .
Statistical Analysis
Figures for RNAscope and IHC are representative of sections obtained from three animals. Data for Figure 4 , expressed as the mean ± SEM (sections obtained from five animals), were analyzed using one-way analysis of variance (ANOVA) with Bonferroni's multiple comparison post hoc test using GraphPad Prism software v.5.0 (Graphpad). A p-value < 0.05 was considered statistically significant.
RESULTS
Validation of CCL5 mRNA Probe
Several antibodies against CCL5 exhibit non-specific binding to an antigen as determined by positive reactions in brain sections from WT and CCL5 KO mice (Supplementary Figure S1) . Thus, we used in situ hybridization to map the expression of CCL5 mRNA. Rat and mouse CCL5 mRNA share high sequence similarity (>90%). Therefore, we first validated the specificity of the CCL5 probe for RNAscope by comparing CCL5 mRNA signal in brain sections from WT and CCL5 KO mice. In the cortex ( Figure 1A ) and corpus callosum ( Figure 1D ) of WT mice, the CCL5 probe produced a strong fluorescent signal, characterized by red dots co-localizing with DAPI positive cells (insets in Figures 1A,D) , suggesting a nuclear localization. Moreover, we observed that only a subpopulation of cells expresses CCL5 mRNA, evidenced by the lack of red puncta in several DAPI-stained nuclei ( Figures 1A,D) . No FIGURE 1 | Validation of CCL5 mRNA probe using CCL5 knock-out (KO) mice. In situ hybridization was performed with an RNAscope probe targeting CCL5 mRNA. Representative images for CCL5 mRNA (red dots) and nuclei counterstained with DAPI (blue) in the cortex (A-C) and corpus callosum (D-F) of wild-type (WT) (A,D) and KO (B,E) mice. The sections were also analyzed for peptidylprolyl isomerase B mRNA (C,F) as positive control probe. Insets: high magnification images depicted by the white arrows. Images showed that the fluorescent in situ hybridization by the RNAscope probe produces puncta (red dots) that represents a single mRNA transcript. Scale bar 50 µm for (A-F) and 20 µm for inset images.
hybridization was observed in CCL5 KO mice (Figures 1B,E) , supporting the specificity of the CCL5 mRNA probe used for RNAscope .
Additional controls for potential artifacts were performed. Sections were stained with a positive control probe that targeted the peptidylprolyl isomerase B gene. This gene is ubiquitously expressed throughout the mice tissue (Kouadjo et al., 2007) . In a parallel experiment, sections were stained with a probe that targeted the Bacillus subtilis dihydrodipicolinate reductase gene. This was used as a negative control because this bacterial gene is not expressed in mice. While peptidylprolyl isomerase B probe detected an mRNA species throughout the brain ( Figures 1C,F) , the negative control probe generated no fluorescence (data not shown) suggesting that the technique and conditions used do not create artifacts.
Detection of CCL5 mRNA in the Rat Brain
RNAscope was then used to map the expression of CCL5 mRNA throughout the adult rat brain. Figures 2A-C show a schematic representation of three representative coronal FIGURE 2 | Distribution of CCL5 mRNA positive cells in the rat brain. (A-C) Schematic drawing of three coronal sections of the rat brain indicating where CCL5 mRNA puncta (red dots) were detected. (A1-A3) Representative sections through the corpus callosum (cc) and cingulate cortex (cg), external capsule (ec) and caudate/putamen (CPu), and anterior commissure (Ac). (B1) Representative section through the cerebral cortex denoting CCL5 mRNA punta in different cortical layers (II-IV). (B2) Representative section through the thalamus; ic, internal capsule; Po, posterior thalamic nucleus; VPM, ventroposterior medial nucleus; VPL, ventroposterior lateral nucleus; (B3,B4) representative sections through the hippocampal formation; LDVL, laterodorsal tegmental nucleus; slu, stratum lucidum of the hippocampus; gr, gracile fasciculus; ml, medial lemniscus; cx, parietal cortex; DG, dentate gyrus; (CA1-4), Cornu Ammonis 1-4. (C1) Representative section from the midbrain; scp, superior cerebellar peduncle; SNc, substantia nigra compacta; MZMG, marginal zone of the medial geniculate nucleus; sc, superior colliculus; DpME, deep mesencephalic nucleus; PAG, periaqueductal gray; DMPAG, dorsomedial PAG; IF, interfascicular nucleus; VTA, ventral tegmental area. Scale bar 50 µm for (A1-C1).
brain sections (0.20 mm, −3.30 mm and −5.30 mm from Bregma) where CCL5 mRNA was detected. Puncta were observed throughout the brain, although some regions contained more puncta than others ( Table 1) . For instance, the corpus callosum (cc, Figure 2A1 ) and the anterior commissure (Ac, Figure 2A3 ) contained more puncta than the caudate/putamen (CPu, Figure 2A2 ). In the cerebral cortex, more hybridization was observed in layers III/IV than II and VI (Figure 2B1) . In the thalamus, the ventroposterior medial (VPM) nucleus exhibited more CCL5 mRNA hybridization than the ventroposterior lateral (VPL) nucleus (Figure 2B2) . Within the hippocampus, CCL5 mRNA was more abundant in the fornix than in the hippocampal formation (Figures 2B3,B4) . In the midbrain, areas with CCL5 mRNA signal included the cerebral peduncles (CP, Figure 2C ), and the ventral tegmental area (VTA, Figure 2C1 ). Semi-quantitative analyses revealed that CCL5 mRNA is expressed in several brain regions, in agreement with previous studies , but that there is an overall higher expression of CCL5 mRNA in areas containing fiber tracts. These include the corpus callosum, anterior commissure, external capsule, fimbria, optic tract and cerebral peduncle (Table 1) . Moreover, we observed CCL5 mRNA positive signal in several brain areas, including the cerebral cortex, striatum, hippocampus, thalamus and midbrain ( Table 1) . Within these brain structures, CCL5 mRNA was detected only in selected areas. For instance, the piriform cortex was negative ( Table 1) . In the striatum, the dorsomedial portion exhibited more CCL5 mRNA signal than the ventromedial one ( Table 1) . Taken together, our data suggest that different cell type may express CCL5 mRNA.
Glial Expression of CCL5 mRNA in the Corpus Callosum
Our semi-quantitative analysis indicates that CCL5 mRNA is most abundant in the white matter that contains fiber tracts (Table 1) which includes several subtypes of glial cells. To reveal which cells express CCL5 mRNA, we examined the corpus callosum utilizing RNAscope in situ hybridization combined with immunohistochemistry for specific glial cell markers. These include GFAP, an astrocytic marker, Iba-1, a microglia/macrophage-specific marker, and Nkx2.2, a marker to identify oligodendrocyte progenitor cells. We found that CCL5 mRNA in the corpus callosum is predominantly inside nuclei of cells, evidenced by the co-localization of DAPI (blue) with the CCL5 mRNA hybridization signal, that were in GFAP ( Figures 3A1-4) , Iba-1 (Figures 3B1-4 ) and Nkx2.2 ( Figures 3C1-4) positive cells. Noteworthy, Nkx2.2 positive cells were aligned in parallel rows (Figure 3C3 ), which is a typical property of adult oligodendrocyte progenitor cells. Quantitative analyses of CCL5 mRNA in the corpus callosum revealed that 53.3%, 31.4% and 72.4% of GFAP, Iba-1 and Nkx2.2 positive cells, respectively, expressed CCL5 mRNA while no CCL5 mRNA was found in neurons ( Figure 4A) . These results validate the notion that the corpus callosum contains a high percentage of oligodendrocytes expressing CCL5 mRNA.
CCL5 mRNA Subcellular Distribution in the Cerebral Cortex
Analysis of the somatosensory cortex with the CCL5 probe revealed that layers III-V contained CCL5 mRNA, although most of the puncta were in layers III and IV ( Figure 2B1) . To characterize which cells express CCL5 mRNA in these layers, serial sections were examined by RNAscope in situ hybridization combined with immunohistochemistry, using glial specific markers as described above. The neuron-specific nuclear protein marker, NeuN, was used to detect neurons. We observed that the fluorescent puncta of CCL5 mRNAs in layers III and IV were co-localized with NeuN ( Figures 5A1-4) , Iba-1 (Figures 5B1-4) , as well as GFAP (Figures 5C1-4) positive cells. More positive puncta were observed in FIGURE 3 | CCL5 mRNA in the corpus callosum is expressed by glia cells. Representative images of coronal sections showing the distribution of red dots in the corpus callosum. Positive CCL5 mRNA hybridization was observed in GFAP (A1-3), Iba-1 (B1-3), and Nkx2.2 (C1-3) positive cells. Panels (A4-C4) are higher magnifications of the areas shown by arrows. DAPI (blue) was used as a counterstaining to show nuclei. cc, corpus callosum; cg, cingulate gyrus. Scale bar = 50 µm for (A1-3,B1-3,C1-3); 20 µm for (A4-C4).
glial cells (Figures 5B4,C4 ) than neurons ( Figure 5A4) , suggesting that cortical neurons express CCL5 mRNA in low abundance. Although we did not quantify CCL5 protein levels due to the lack of specificity of the antibodies, this result supports previous in vitro data that neurons produce and release CCL5 protein at a lower level than glial cells (Avdoshina et al., 2010) . In layer V, CCL5 mRNA was also observed in Nkx2.2 positive cells ( Figures 5D1-4) , overall suggesting that in the cerebral cortex glia cell as well neurons express CCL5 mRNA. To confirm this finding, we carried out a quantitative analysis of CCL5 mRNA puncta, 48.9% of neurons, 44.1% of astrocytes, 12% of microglia and 13.3% oligodendrocytes were also positive for CCL5 mRNA ( Figure 4B) .
Neurons in the Hippocampus Express CCL5 mRNA
Analysis of the hippocampal formation revealed that CCL5 mRNA is particularly abundant in the fimbria (Figure 2B3 ), which is a prominent white matter tract along the edge of the hippocampus, supporting the notion that CCL5 mRNA is expressed in fiber tracts. However, red puncta were also observed in sections throughout the hippocampus mainly in the Cornu Ammonis (CA)1 and dentate gyrus (DG) regions ( Figure 2B4) . The CA1 contains pyramidal neurons whereas the polymorphic layer of the DG consists of sparsely distributed polymorphic cells. RNAscope in situ hybridization combined with immunohistochemistry revealed that in the CA1 region, in addition to neurons (Figures 6A1-4) , microglia ( Figures 6B1-4) and oligodendrocytes ( Figures 6E1-4) expressed CCL5 mRNA. In neurons, the red puncta that correspond to CCL5 mRNA were found outside and inside the nuclei (Figure 6A4) , suggesting that some of this mRNA is readily available for translation. In the polymorphic cells layer of the DG, microglia (Figures 6C1-4) and astrocytes ( Figures 6D1-4) were positive for CCL5 mRNA. Overall, in the hippocampus, CCL5 mRNA was found in 73.2% of neurons and in ∼20% in glial cells ( Figure 4C ).
CCL5 mRNA Is Expressed in a Subset of Dopaminergic Neurons in the Midbrain
CCL5 mRNA was also scattered in the midbrain (Figure 2C1) . The majority of puncta were observed in the cerebral peduncle ( Figure 2C) , a major descending fiber tract. However, puncta were also observed within the VTA region. RNAscope in situ hybridization followed by immunohistochemistry revealed that in this region, 79% of neurons ( Figure 4D ) express CCL5 mRNA ( Figures 7A1-4) . Microglia ( Figures 4D, 7B1-4) , astrocytes ( Figures 7D1-4) , and few oligodendrocytes ( Figures 4D, 7C1-4 ) also express CCL5 mRNA in 11.4%, 13.7%, and 5.9% respectively. Intriguingly, only a subpopulation of NeuN positive cells expressed CCL5 mRNA (Figure 7A3) . To determine the type of neurons that express CCL5 mRNA, sections were stained with an antibody against TH, the rate limiting step enzyme for the synthesis of dopamine. Some but not all TH-positive cells exhibited CCL5 mRNA puncta (Figures 7E1-3) , suggesting that CCL5 mRNA is synthesized in a small subset of dopamine neurons. Interestingly, these neurons, unlike those in the cerebral cortex, exhibited several puncta, mostly perinuclearly ( Figure 7E4) , suggesting high expression of this mRNA in these neurons.
DISCUSSION
Our results reveal a unique expression profile of CCL5 mRNA throughout the adult rodent brain. We showed that the cellular anatomical distribution of this chemokine is highly regionalized and restricted to certain parts of the brain. Most notably, we found that CCL5 mRNA hybridization signal is the highest in white matter, such as the anterior commissure, corpus callosum and the optic tract, which are rich in glia cells and myelinated axons. However, a constitutive expression of CCL5 mRNA was also present in some subset of neuronal cell in the cerebral cortex and hippocampus, and especially in dopamine-producing neurons of the VTA. Altogether, our data characterize a constitutively anatomical and cellular expression of CCL5 mRNA in the rat brain. Most importantly, we observed CCL5 mRNA in various cells even without injury or inflammation.
Our work joins a growing number of studies that have shown that chemokines can be constitutively expressed throughout the brain in a region specific manner. For example, CX3CL1, the first chemokine shown to be expressed in neurons, is constitutively expressed in human (Raport et al., 1995) and rat brain (Nishiyori et al., 1998) . CXCL12, also known as stromal derived factor-1, is expressed in different cell types throughout the rat brain, including astrocytes, microglia, and neurons (Banisadr et al., 2003) . Similarly, CCL2 is constitutively expressed in neurons and astrocytes, but not in oligodendrocytes or microglia (Banisadr et al., 2005) . Our data shows that under physiological conditions CCL5 mRNA is constitutively expressed in all glial cells (microglia, astrocytes and oligodendrocytes) as well as in a subset of neurons. Although in this work we only measured mRNA, the fact that CCL5 proteins are detected in the adult brain supports the notion that CCL5, like other chemokines (Banisadr et al., 2003) , might have a role as potential modulators of brain function.
Under physiological conditions, CCL5 is expressed in low abundance in the brain tissue, posing an experimental challenge to detect it with conventional immunostaining technology. In addition, levels of a given peptide do not necessarily reflect the site of synthesis. An alternative approach is measuring mRNA by RNAscope technology, which in addition to the sensitivity for the detection of low abundance mRNA molecules (Sørdal et al., 2013) . In our study, we were able to observe low number of puncta within cells, as well as an agglomerate of puncta. The highest hybridization signal was mostly observed in glial cells. Moreover, in several sections, we have seen puncta in DAPI positive cells, suggesting a nuclear localization. However, CCL5 mRNA was also localized outside the nucleus. Thus, it appears that from the nucleus, CCL5 mRNA might move to the cytoplasm, where the translation into CCL5 protein occurs. This event could be followed by CCL5 release. Although measuring CCL5 release in vivo is technically challenging, this notion is supported by previous data showing that brain cells in vitro release CCL5 proteins (Avdoshina et al., 2010) .
A novel discovery presented here is the expression of CCL5 mRNA in oligodendrocytes. The significance of this result is still under investigation. CCL5 promotes the proliferation of an oligodendrocyte precursor-like cell line (Kadi et al., 2006) . Thus, it is possible that oligodendrocyte precursors or other glial cells might be regulating their own proliferation via the release of CCL5. Oligodendrocyte most well known role is to FIGURE 6 | Distribution of CCL5 mRNA in the hippocampus. Images are representative coronal sections showing the distribution of CCL5 mRNA (red dots) in the dentate gyrus (DG) and CA1 regions of the hippocampus. The sections were stained for NeuN (A1-3), Iba-1 (B1-3,C1-3), GFAP (D1-3), or Nkx2.2 (E1-3). DAPI (blue) was used as a counterstaining. Panels (A4-E4) are higher magnifications of areas pointed by arrows. Scale bar = 50 µm for (A1-E3), and 20 µm for high magnification images (A4-E4). preserve myelin; however, oligodendrocytes also maintain axonal integrity, support axonal metabolism and aid neuronal survival (Peferoen et al., 2014) . Changes in oligodendrocytes number and dynamics are increasingly recognized as important components in the pathogenesis of neurodegenerative disorders. In taiep rats, an animal model for multiple sclerosis, CCL5 and its receptor CCR5 is down-regulated in comparison to SpragueDawley rats (Soto-Rodriguez et al., 2015) . Such reduction has been shown to limit the infiltration of pro-inflammatory macrophages and therefore to prevent demyelination (Glass et al., 2001 ). On the other hand, CCL5 has neuroprotective properties. For example, CCL5 has been shown to exert neuroprotective activity against various neurotoxins including glutamate (Bruno et al., 2000) , β-amyloid (Ignatov et al., 2006) , and the viral proteins gp120 (Campbell et al., 2015) and Tat (Rozzi et al., 2014) . The neuroprotective activity of CCL5 could be due to its ability to increase neurotrophic factors, such as brain-derived neurotrophic factor and epidermal growth factor (Tokami et al., 2013) . Thus, it is conceivable to suggest that oligodendrocyte-derived CCL5 could act as a regulator of neuronal survival.
Our studies showed that some neuronal populations in selected brain areas exhibit CCL5 mRNA. CCL5 is not the only chemokine that is expressed in neurons. For example, CCL2 is constitutively expressed in neurons, and co-localizes with various neurotransmitters and neuropeptides (Banisadr et al., 2005) . FIGURE 7 | Dopamine neurons express CCL5 mRNA. Representative images of coronal sections through the VTA. CCL5 mRNA (red dots) was detected in DAPI (blue) positive nuclei of neurons (A1-3), microglia (B1-3), oligodendrocytes (C1-3) and astrocytes (D1-3). CCL5 mRNA is also expressed in tyrosine hydroxylase (TH) positive cells (E1-3). Panels (A4-E4) are higher magnifications of areas pointed by arrows. Scale bar = 50 µm for (A1-E3), and 20 µm for high magnification images (A4-E4).
Also, CXCL12, CXCL14 and CX3CL1 are expressed in neurons in several brain regions (Nishiyori et al., 1998; Banisadr et al., 2011) . In addition, neurons, at least in culture, are capable of releasing CCL5 upon depolarization or activation of N-methyl-D-aspartate receptors , suggesting that neurons, under the proper stimulation, are capable of releasing CCL5, not dissimilar to that observed for neurotransmitters.
Here, we show that NeuN positive cells in the cerebral cortex and in the hippocampus are also CCL5 mRNA positive; together with previous findings that cortical neurons release CCL5 (Avdoshina et al., 2010) , our data suggest that CCL5 mRNA can be translated into proteins in neurons. Moreover, few TH-positive cells in the VTA expressed CCL5 mRNA, indicating that CCL5 may be expressed by a subset of dopaminergic neurons. Why CCL5 mRNA is detected only a subset of dopamine neurons is at present unclear. The VTA also contains GABAergic neurons (Dobi et al., 2010) . Thus, the co-localization of CCL5 mRNA in TH-negative but NeuN positive cells in the VTA suggests that CCL5 mRNA may be synthetized in GABAergic neurons. More experiments are needed to support this suggestion.
Our data show that CCL5 mRNA is contained in a subset of dopaminergic neurons. The significance of this finding remains speculative at present. Dopamine neurons of the VTA belong to the dopaminergic mesolimbic system, which comprises several interconnected brain regions, including the nucleus accumbens and the prefrontal cortex. Activation of this system is crucial for the reward and addictive properties of opioids (Wise and Rompre, 1989; Pontieri et al., 1995) . We have previously shown that CCL5 protein levels are increased in morphine dependent rats in brain areas involved in opioid reward . CCL5 has also been shown to interact with opioid receptors causing heterologous desensitization (Szabo et al., 2002) . Thus, CCL5, when produced in dopaminergic fibers innervating the nucleus accumbens or prefrontal cortex could be contributing to regulation of dependence to opioids as previously suggested . CCL5 might act as a neuromodulator to enhance/inhibit the synaptic transmission underlying opioid reward. Although still speculative, this suggestion is supported by data showing that CCR5, the receptor for CCL5, is expressed in selected neuronal populations of the frontal cortex and striatum (Avdoshina et al., 2011) . Moreover, CCL5 increases the release of glutamate (Musante et al., 2008; Di Prisco et al., 2012) whose activity could induce various forms of synaptic plasticity and cellular adaptations that are responsible for opioid tolerance and addiction (Manzoni and Williams, 1999; Stuber et al., 2010 Stuber et al., , 2011 .
In conclusion, we were able to detect CCL5 mRNA by in situ hybridization in adult rat brain in several cells, including a subset of neurons. Together with previous results showing that CCL5 and its receptor CCR5 are constitutively produced in the adult rodent brain (Tran et al., 2007; Avdoshina et al., 2011; Campbell et al., 2013) , our data suggest a role for CCL5 in the CNS other than a homeostatic chemokine that attracts and activates mononuclear phagocytes at sites of inflammation.
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